Ironwood Pharmaceuticals (IRWD) Non-Current Debt (2013 - 2026)

Ironwood Pharmaceuticals has disclosed Non-Current Debt across 11 years of filings, most recently posting $385.0 million for Q2 2026.

• In Q2 2026, Non-Current Debt changed 0.0% year-over-year to $385.0 million; the TTM figure through Jun 2026 stood at $385.0 million (changed 0.0% YoY), while the FY2025 annual figure was $385.0 million, changed 0.0% from the prior year.
• Non-Current Debt came in at $385.0 million for Q2 2026 at Ironwood Pharmaceuticals, roughly flat from $385.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $425.0 million in Q2 2024 to a low of $275.0 million in Q1 2024.
• Average Non-Current Debt over 4 years is $370.8 million, with a median of $385.0 million recorded in 2024.
• The largest YoY upside for Non-Current Debt was 40.0% in 2025 against a maximum downside of 9.41% in 2025.
• Over 4 years, Non-Current Debt stood at $300.0 million in 2023, then rose by 28.33% to $385.0 million in 2024, then changed by 0.0% to $385.0 million in 2025, then changed by 0.0% to $385.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $385.0 million in Q2 2026, $385.0 million in Q1 2026, and $385.0 million in Q4 2025.